Literature DB >> 8173406

Cancer of the head and neck.

J S Tobias1.   

Abstract

Cancers of the upper aerodigestive tract, collectively known as head and neck cancers, arise from a multiplicity of sites. In the West, excess tobacco and alcohol consumption are the most important of the known predisposing factors; elsewhere in the world, notably in India and China, the aetiology, pattern of primary sites, and clinical behaviour are different. Clinically these tumours pose exceptional problems in management, and skilled multidisciplinary teams are necessary in order to achieve the highest level of service and research. Historically, surgery and radiotherapy have been the most important treatment modalities; chemotherapy is now increasingly employed but not yet fully established. Successful rehabilitation of patients with head and neck cancers requires access to high quality speech therapists and other support staff with training in functional pharyngeal disorders. Current research efforts are largely directed towards defining the proper role of chemotherapy and assessing the possible advantage of unconventional radiation approaches. In recent years the roles of primary, reconstructive, and salvage surgery have also become better defined. Many patients are suitable for randomisation into ongoing prospective clinical trials which have been specifically designed to address these issues.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8173406      PMCID: PMC2539765          DOI: 10.1136/bmj.308.6934.961

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  14 in total

1.  Concomitant boost radiotherapy schedules in the treatment of carcinoma of the oropharynx and nasopharynx.

Authors:  K K Ang; L J Peters; R S Weber; M H Maor; W H Morrison; C D Wendt; B W Brown
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-12       Impact factor: 7.038

Review 2.  Head and neck cancer: prognostic factors for response to chemotherapy.

Authors:  M Clavel; A R Maged Mansour
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

3.  Changing incidence of cancer of the tongue, oral cavity, and pharynx in Denmark.

Authors:  H Møller
Journal:  J Oral Pathol Med       Date:  1989-04       Impact factor: 4.253

4.  A randomised clinical trial to contrast radiotherapy with radiotherapy and methotrexate given synchronously in head and neck cancer.

Authors:  N K Gupta; R C Pointon; P M Wilkinson
Journal:  Clin Radiol       Date:  1987-11       Impact factor: 2.350

5.  Improving the poor prognosis of oral squamous cell carcinoma.

Authors:  I Hutchison
Journal:  BMJ       Date:  1994-03-12

Review 6.  The internist in the management of head and neck cancer.

Authors:  C Jacobs
Journal:  Ann Intern Med       Date:  1990-11-15       Impact factor: 25.391

7.  Radioimmunodetection of lymph node invasion in prostatic cancer. The use of iodine 123 (123I)-labeled monoclonal anti-prostatic acid phosphatase (PAP) 227 A F(ab')2 antibody fragments in vivo.

Authors:  M Leroy; P Teillac; J D Rain; J C Saccavini; A Le Duc; Y Najean
Journal:  Cancer       Date:  1989-07-01       Impact factor: 6.860

Review 8.  Has chemotherapy proved itself in head and neck cancer?

Authors:  J S Tobias
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

9.  Combined bleomycin and radiotherapy in oral cancer.

Authors:  V Shanta; S Krishnamurthi
Journal:  Clin Radiol       Date:  1980-09       Impact factor: 2.350

10.  Adjuvant chemotherapy in head and neck cancer.

Authors:  P M Stell; N S Rawson
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

View more
  15 in total

1.  Multidisciplinary team a prerequisite in the management of head and neck cancer?

Authors:  Jan Olofsson
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-02       Impact factor: 2.503

2.  Registration of drugs for treating cancer and HIV infection: a plea to carry out phase 3 trials before admission to the market.

Authors:  P P Koopmans
Journal:  BMJ       Date:  1995-05-20

3.  Paediatric orofacial tumours: new oral health concern in paediatric patients.

Authors:  F O Omoregie; O Akpata
Journal:  Ghana Med J       Date:  2014-03

4.  Gemcitabine-based induction chemotherapy and concurrent with radiation in advanced head and neck cancer.

Authors:  Doaa Ali Sharaf El Deen; Eman Abd Elkareem Toson; Shawky Mahmoud El Morsy
Journal:  Med Oncol       Date:  2012-06-08       Impact factor: 3.064

5.  Gemcitabine concurrent with radiation therapy for locally advanced head and neck carcinomas.

Authors:  Ashok Chauhan; Harmeet Singh; Tejpal Sharma; K K Manocha
Journal:  Afr Health Sci       Date:  2008-09       Impact factor: 0.927

6.  Uptake and fate of surface modified silica nanoparticles in head and neck squamous cell carcinoma.

Authors:  Emina Besic Gyenge; Xenia Darphin; Amina Wirth; Uwe Pieles; Heinrich Walt; Marius Bredell; Caroline Maake
Journal:  J Nanobiotechnology       Date:  2011-08-11       Impact factor: 10.435

7.  Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial.

Authors:  Jeffrey S Tobias; Kathryn Monson; Nirmal Gupta; Hugh Macdougall; John Glaholm; Iain Hutchison; Latha Kadalayil; Allan Hackshaw
Journal:  Lancet Oncol       Date:  2009-10-29       Impact factor: 41.316

Review 8.  Current evidence on the burden of head and neck cancers in Nigeria.

Authors:  Opubo B da Lilly-Tariah; Abayomi O Somefun; Wasiu L Adeyemo
Journal:  Head Neck Oncol       Date:  2009-05-28

9.  Cannabis use and cancer of the head and neck: case-control study.

Authors:  Sarah Aldington; Matire Harwood; Brian Cox; Mark Weatherall; Lutz Beckert; Anna Hansell; Alison Pritchard; Geoffrey Robinson; Richard Beasley
Journal:  Otolaryngol Head Neck Surg       Date:  2008-03       Impact factor: 3.497

10.  Consensus standards for the process of cancer care: a modified expert panel method applied to head and neck cancer. South and West Expert Tumour Panel for Head and Neck Cancer.

Authors:  M A Birchall
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.